Paul G. Richardson

TL;DR: Patients treated with VMP more frequently experienced a sustained HRQoL improvement in most of the EORTC QLQ-C30 domains than patients in the MP arm after best tumor response, and the likelihood of a sustained improvement in Nausea and Diarrhea was significantly higher in VMP patients, independent of the type of response and the respective symptom score.

TL;DR: This study aimed to determine activity and safety of weekly bortezomib and temsirolimus in patients with relapsed/refractory Multiple Myeloma and observed responses observed among 32 patients refractory to their most recent bortzomib therapy.

TL;DR: Melflufen was evaluated in combination with low dose dexamethasone (dex) in a Phase 1/2a study of melphalan in patients with RRMM with measurable disease and at least 2 prior lines of therapy to determine the maximally tolerated dose (MTD).

TL;DR: An integrated analysis of pts from 4 phase 1/2 studies who did not undergo autologous stem cell transplant (ASCT) and received ixazomib maintenance therapy found overall response rate was 93% after induction and 94% after maintenance, and combined mean dose intensity during maintenance was 89.1%.

TL;DR: Within the limits of this analysis, the OS of patients with at least triple‐class‐refractory MM was significantly better with Sel‐dex versus available therapies, suggesting that Sel-dex may be associated with a meaningful OS benefit in these patients.